Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Comment by duskwon Mar 02, 2011 2:41pm
233 Views
Post# 18220538

RE: RE: Market didn't like the news???

RE: RE: Market didn't like the news???Actually the prospectus clearly stated that the funds are not required to fund operating losses.

"For the interim period ended September 30, 2010, the Corporation had negative net cash flow from operating activities. The net proceeds from the Offering will not be used to fund this negative net cash flow from operating activities. The Corporation expects that it will be able to fund future anticipated negative net cash flow from operating activities, if any, from existing working capital and cash generated from operating activities. See "Risk Factors" and "Note Regarding Forward Looking Statements"."

Also, one reason for the share price drop is that the private placement marketters are now likely busy selling the shares they've aquired instead of buying more on the open market. There is no doubt this will create some overhang until the fundamentals become clearer.

i.e.

"The Corporation has been advised by the Underwriters that, in connection with the Offering, the Underwriters may effect transactions which stabilize or maintain the market price for the Common Shares at levels other than those which otherwise might prevail in the open market. Such transactions, if commenced, may be discontinued at any time. See "Plan of Distribution"."

Bullboard Posts